title: INPP4B suppresses prostate cancer cell invasion.
abstract: BACKGROUND
  INPP4B and PTEN dual specificity phosphatases are frequently lost during progression of prostate cancer to metastatic disease. We and others have previously shown that loss of INPP4B expression correlates with poor prognosis in multiple malignancies and with metastatic spread in prostate cancer.
  
  
  RESULTS
  We demonstrate that de novo expression of INPP4B in highly invasive human prostate carcinoma PC-3 cells suppresses their invasion both in vitro and in vivo. Using global gene expression analysis, we found that INPP4B regulates a number of genes associated with cell adhesion, the extracellular matrix, and the cytoskeleton. Importantly, de novo expressed INPP4B suppressed the proinflammatory chemokine IL-8 and induced PAK6. These genes were regulated in a reciprocal manner following downregulation of INPP4B in the independently derived INPP4B-positive LNCaP prostate cancer cell line. Inhibition of PI3K/Akt pathway, which is highly active in both PC-3 and LNCaP cells, did not reproduce INPP4B mediated suppression of IL-8 mRNA expression in either cell type. In contrast, inhibition of PKC signaling phenocopied INPP4B-mediated inhibitory effect on IL-8 in either prostate cancer cell line. In PC-3 cells, INPP4B overexpression caused a decline in the level of metastases associated BIRC5 protein, phosphorylation of PKC, and expression of the common PKC and IL-8 downstream target, COX-2. Reciprocally, COX-2 expression was increased in LNCaP cells following depletion of endogenous INPP4B.
  
  
  CONCLUSIONS
  Taken together, we discovered that INPP4B is a novel suppressor of oncogenic PKC signaling, further emphasizing the role of INPP4B in maintaining normal physiology of the prostate epithelium and suppressing metastatic potential of prostate tumors.
authors.forename: Myles C
authors.initials: MC
authors.lastname: Hodgson
authors.forename: Elena I
authors.initials: EI
authors.lastname: Deryugina
authors.forename: Egla
authors.initials: E
authors.lastname: Suarez
authors.forename: Sandra M
authors.initials: SM
authors.lastname: Lopez
authors.forename: Dong
authors.initials: D
authors.lastname: Lin
authors.forename: Hui
authors.initials: H
authors.lastname: Xue
authors.forename: Ivan P
authors.initials: IP
authors.lastname: Gorlov
authors.forename: Yuzhuo
authors.initials: Y
authors.lastname: Wang
authors.forename: Irina U
authors.initials: IU
authors.lastname: Agoulnik
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D002465:Cell Movement; D049109:Cell Proliferation; D051546:Cyclooxygenase 2 / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic; D057809:HEK293 Cells; D006801:Humans; D007211:Indoles / Q000494:pharmacology; D051034:Inhibitor of Apoptosis Proteins / Q000378:metabolism; D016209:Interleukin-8 / Q000235:genetics; D008297:Male; D008301:Maleimides / Q000494:pharmacology; D016513:Mice, SCID; D009361:Neoplasm Invasiveness; D010744:Phosphoric Monoester Hydrolases / Q000235:genetics / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000473:pathology*; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000378:metabolism*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D034741:RNA, Small Interfering / Q000235:genetics; D000077022:Survivin; D054462:p21-Activated Kinases / Q000235:genetics
chemical_list: C107489:BIRC5 protein, human; D007211:Indoles; D051034:Inhibitor of Apoptosis Proteins; D016209:Interleukin-8; D008301:Maleimides; D047428:Protein Kinase Inhibitors; D034741:RNA, Small Interfering; D000077022:Survivin; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; C429007:PAK6 protein, human; D054462:p21-Activated Kinases; D011493:Protein Kinase C; D010744:Phosphoric Monoester Hydrolases; C053153:phosphatidylinositol-3,4-bisphosphate 4-phosphatase; C070515:bisindolylmaleimide I